The historical rank and industry rank for Hyloris Pharmaceuticals's Net Margin % or its related term are showing as below:
LTS:0AB6'
s Net Margin % Range Over the Past 10 Years
Min: -6363.74 Med: -1322.89 Max: -74.98
Current: -87.89
LTS:0AB6's Net Margin % is ranked better than 50.32% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs LTS:0AB6: -87.89
Hyloris Pharmaceuticals (LTS:0AB6) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Hyloris Pharmaceuticals Net Margin % Related Terms
Hyloris Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (LTS:0AB6) has a Net Margin % of -66.34% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Hyloris Pharmaceuticals and its competitors. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #470 out of 946 companies in the Biotechnology industry, placing it in the top 49.7%.
Is Hyloris Pharmaceuticals' Net Margin % too high?
Hyloris Pharmaceuticals' current Net Margin % is -66.34%. Based on the distribution chart, Hyloris Pharmaceuticals ranks #470 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #470 out of 946 companies for Net Margin %. This puts Hyloris Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Net Margin % is -66.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.49, compared to a current price of €4.52 — trading 52.4% below its estimated fair value. The current Net Margin % is -66.34%. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Net Margin % is -66.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.52 is trading 52.4% below its estimated GF Value™ of €9.49.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
Net Margin %: -66.34%
GF Value™: €9.49 vs. price of €4.52 (52.4% below fair value)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score
Get the complete analysis for LTS:0AB6
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
